Overview
The Cantor Biotech Equity Research Team hosted its 2023 Virtual Brain Week 2 from Tuesday, December 12, to Friday, December 15, 2023. Cantor’s Virtual Brain Week 2 featured interactive discussions, fireside chats, and panel presentations focusing on Neuro-Innovators that develop and commercialize medicines for high unmet need indications in the Neurology & Psychiatry industries.
- Summarized of “lessons learned” following Fall/Winter ’23 clinical conferences, including:
- CTAD
- AES
- SFN
- ACNP
- WorldSleep
- WorldMuscle
- ObesityWeek
- Reviewed clinical impact and broadening commercial prospects of recently approved rare disease therapeutics
- Outlined key drivers of adoption for ACAD’s DAYBUE (Rett Syndrome) and RETA’s SKYCLARYS (Friedreich’s Ataxia)
- Discussed emerging paradigm shifters (e.g., LEQEMBI) that paves the way for regulatory success and bolstered confidence in regulatory process and Neuro-Innovation
- KOL panels on key topics in Neurology/Psychiatry/Endocrinology
- Previewed impactful newsflow/data that may set the stage for alpha generation by investing in practice-change neuro/psych therapies in 2024
- Fireside chats with senior management of selected Neuro-Innovator companies
- Virtual NDR meetings with selected Neuro-Innovator companies by request